What Vetoquinol does

Vetoquinol S.A. is a France-based, publicly listed (Euronext Paris: VETO) animal health pharmaceutical company founded in 1933, headquartered in Lure (Magny-Vernois) and operating as a family-owned pure-play in veterinary medicines. The company develops, manufactures, and commercializes veterinary drugs and non-medicated products for companion animals (dogs, cats) and farm animals (cattle, pigs, poultry), organized into an 'Essential' portfolio of market-leading and potentially leading brands (64% of 2025 sales at €334.5 million) and a complementary portfolio addressing broader market needs. The Essential range spans eight therapeutic domains — anti-parasite, mobility/pain/inflammation, dermatology, udder health, antibiotics, reproduction, internal medicine, and cardio-nephrology — anchored by brands such as Drontal, Profender, Tolfine, Clavaseptin, UpCard, Propalin, Felpreva, and Simplera, plus non-medicated products including Flexadin, Zylkène, Sonotix, and Calf Lyte. Recent product launches (Felpreva in 2023, Simplera in 2022) and the February 2025 acquisition of MediVet Biologics demonstrate active pipeline replenishment, supported by R&D centers in France, the United States, Poland, and Brazil with annual R&D spending of €43.7 million in 2024 (8.1% of sales).

Vetoquinol generated 2025 sales of €526 million (0.2% growth at constant exchange rates), EBIT of €91.5 million (17.4% margin), and net income of €57.3 million, holding a net cash position of €205.8 million. The company ranked as the 8th largest animal health pharmaceutical company globally in 2023 and operates through 24 subsidiaries plus distributor networks reaching approximately 100 countries, with Europe representing roughly 50% of sales and the Americas (especially the US) and Asia-Pacific providing the remaining geographic balance. The go-to-market is sales-led, relying on direct field sales teams and veterinary distribution channels across multiple species and therapeutic segments. Revenue is generated through one-time product sales to veterinary professionals and clinics rather than subscription or licensing models, with pricing administered through veterinary distribution channels and varying by territory and product line. Vetoquinol is led by Chairman and CEO Matthieu Frechin, with corporate governance exercised through a board of directors and a public limited company structure (RCS Gray-Vesoul B 676 250 111).

Name

Vetoquinol

Legal name

Vetoquinol S.A.

Website

https://vetoquinol.com

Company type

Public

Founded year

1933

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Vetoquinol is a France-based, publicly listed (Euronext Paris: VETO) animal health pharmaceutical company developing and commercializing veterinary medicines and non-medicated products for companion animals (dogs, cats) and farm animals (cattle, pigs), selling through 24 subsidiaries in approximately 100 countries with €526 million in 2025 sales.

Ownership category

akta.pro rank

Product category

Animal Health Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Animal Food Manufacturing (3111), Animal Food Manufacturing (31111)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology) (HLAMAIAH), Antimicrobials & Anti-infectives (HLAMAEAE), Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine) (HLAMALAO)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Companion animal care
• Livestock pharmaceuticals
• Parasiticide treatments

Headquarters

HQ city

Lure

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Veterinary Pharmaceuticals and Non-Medicated Products: Vetoquinol generates revenue through the sale of veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats). The company classifies products into Essential (64% of sales, growing 4.1%) and Complementary portfolios.

Go-to-market motion1 record

Core offering

Vetoquinol develops, manufactures, and commercializes veterinary medicines and non-medicated products for companion animals (dogs and cats) and farm animals (cattle and pigs). The Essential products portfolio, comprising 50+ leading or potentially leading products across 3 species and 4 strategic segments, accounts for 64% of 2025 sales (€334.5 million) and spans eight therapeutic domains including anti-parasite, antibiotics, mobility/pain/inflammation, dermatology, udder health, reproduction, internal medicine, and cardio-nephrology. Products are sold under key brands such as Drontal, Profender, Felpreva, Tolfine, Clavaseptin, UpCard, Propalin, Flexadin, Zylkène, Sonotix, Calf Lyte, and Simplera to veterinary clinics and animal health professionals globally.

Product overview

Vetoquinol is an independent, family-owned animal health company that innovates, develops, and commercializes veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats). The company operates a dual portfolio strategy: the Essential products portfolio (constituting 64% of 2025 sales at €334.5 million) comprises market-leading or potentially leading products addressing daily veterinary needs, while complementary products fill broader market requirements. The portfolio spans eight therapeutic domains: Mobility/Pain/Inflammation (including Tolfine®), Dermatology/Hygiene/Care, Udder Health, Anti-Parasite (including Drontal®, Profender®), Antibiotics (including Clavaseptin®), Reproduction, Internal Medicine, and Cardio-Nephrology (including UpCard®), alongside non-medicated products (Flexadin®, Zylkène®, Sonotix®, Calf Lyte®). Recent new product launches include Felpreva® (2023) and Simplera® (2022, US market). Products are organized by species (companion animals, cattle, pigs) and by therapeutic domain. The company maintains R&D facilities primarily in France (Lure) with development units in the US, Poland, and Brazil, investing over €30 million annually in R&D.

Differentiator

Problem solved

Functional benefit

Brands

• Vetoquinol Pro France: Professional portal for French vets, veterinary assistants and pharmacists to access products, tools, webinars and training.

Products and services

• Essential Products Portfolio Portfolio of 50+ veterinary drugs and non-medicated products that are leading or potentially market leaders addressing daily veterinary needs in farm and companion animal segments. Marketed globally and constituting the primary growth driver of the Group, representing 64% of total sales in 2025 (€334.5 million).
• Tolfine® Non-steroidal anti-inflammatory analgesic for veterinary use, leader in its therapeutic domain in France.
• Clavaseptin® Antibiotic medication for companion animals, among the market leaders in France.
• Drontal® Anthelmintic (dewormer) product providing broad-spectrum parasite control for pets and farm animals, acquired as part of external growth strategy.
• Profender® Companion animal parasiticide product providing parasite treatment for cats and dogs, acquired as part of external growth strategy.
• UpCard® Cardiovascular medication for companion animals, among the leading products in its category in France.
• Propalin® Behavioral management medication for dogs, marketed in France.
• Flexadin® Joint health and mobility supplement for dogs and cats, among the leading non-medicated products in France.
• Zylkène® Behavioral support supplement for cats and dogs to help manage stress and anxiety, leading product in its category.
• Sonotix® Ear care product for companion animals, marketed in France.
• Calf Lyte® Calf health product for farm animals, marketed in France.
• Felpreva® Newly launched companion animal product for cats representing the continued expansion of the Essential products portfolio, noted as an illustration of Vetoquinol's innovation dynamism.
• Simplera® New product launched in the US market in late 2022, recorded good performance among 2022-2023 product launches.

Quantifiable outcome

• Essential products sales grew from €151 million in 2014 to €334.5 million in 2025, representing average annual growth of over 8%
• +2 more outcomes

Named customers1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MediVet BiologicscoreStrategic or Co-development Partner · 1 February 2025Vetoquinol acquired MediVet Biologics in February 2025 to accelerate allergen immunotherapy development. This acquisition strengthens Vetoquinol's position in the pet allergy treatment market and expands its biologics capabilities for companion animals.

Scale indicators16 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Norbrook Laboratories: Privately held UK/Ireland-headquartered manufacturer of generic and branded veterinary pharmaceuticals for livestock and companion animals; competes directly with Vetoquinol on parasiticide, anti-infective and anti-inflammatory products in similar channels.
• Virbac: Independent French animal health pharmaceutical company with a similarly diversified companion-animal and livestock therapeutics portfolio worldwide; the most direct like-for-like competitor to Vetoquinol in size, geography and product mix.
• Ceva Santé Animale: France-based, family-controlled multi-species animal health pharmaceutical company that competes with Vetoquinol across companion animals, poultry, swine and ruminants, with comparable global ambitions and product breadth.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology and anaesthesia; its therapeutic focus and channel through veterinary clinics closely mirror Vetoquinol's Essential products strategy (now part of the broader Elanco group but still operated as a distinct business).
• Phibro Animal Health: US-listed animal health company with a strong livestock and nutrition focus (cattle, poultry, swine) and a smaller companion animal portfolio; comparable in scale and in the mix of medicated feed additives and vaccines to Vetoquinol's livestock business.

Emerging players

• Huvepharma: Bulgaria-based, privately-held animal health and nutrition company with growing presence in livestock pharmaceuticals, vaccines and feed additives; an emerging scaled challenger with overlapping livestock therapeutic categories to Vetoquinol's farm-animal business.

Broad incumbents

• Elanco Animal Health: Large, publicly-listed animal health company (~5x the size of Vetoquinol by revenue) covering companion animals, livestock and aquaculture; competes in many of Vetoquinol's key therapeutic categories but from a much larger global commercial base.
• MSD Animal Health (Merck Animal Health): Animal health arm of Merck & Co., a top-tier global player in companion animal parasiticides, livestock vaccines and pharmaceuticals; one of the most influential incumbents competing with Vetoquinol's Essential products portfolio worldwide.
• Boehringer Ingelheim Animal Health: Animal health division of Boehringer Ingelheim, one of the largest global players in veterinary pharmaceuticals and vaccines; competes with Vetoquinol particularly in companion animal parasitides (Drontal/Profender) and livestock vaccines.
• Zoetis: Global market leader in animal health pharmaceuticals and biologics across livestock and companion animals; overlaps with Vetoquinol across parasiticides, vaccines, dermatology and anti-infectives, with substantially greater R&D and commercial resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vetoquinol

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetoquinol